

Adult CIRB - Early Phase Emphasis Meeting Agenda

May 4, 2021

I Continuing Review

10014, A Pilot Study of Atezolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies (Protocol Version Date 11/23/20)

II Continuing Review

10329, Phase I Sequential Trial of Agents Against DNA Repair (STAR) (Protocol Version Date 03/24/21)

III Continuing Review

9881, A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors (Protocol Version Date 02/23/21)

IV Continuing Review

9903, A Phase 1B Study of AZD9291 in Combination with Navitoclax in EGFR-mutant Non-Small Cell Lung Cancer Following Resistance to Initial EGFR Kinase Inhibitor (Protocol Version Date 06/24/20)

V Continuing Review

9984, A Randomized Phase 2 Study of cediranib in Combination with olaparib versus olaparib alone in men with metastatic castration resistant prostate cancer (Protocol Version Date 09/08/20)

VI Continuing Review

EA5162, Phase II Study of AZD9291 (Osimertinib) in Advanced NSCLC Patients with Exon 20 Insertion Mutations in EGFR (Protocol Version Date 06/29/20)

VII Memos

9903, A Phase 1B Study of AZD9291 in Combination with Navitoclax in EGFR-mutant Non-Small Cell Lung Cancer Following Resistance to Initial EGFR Kinase Inhibitor (Protocol Version Date)
